Abstract
Hematopoietic stem cell transplantation (HSCT) is curative for hematological manifestations of Fanconi anemia (FA). We performed a retrospective analysis of 22 patients with FA and aplastic anemia, myelodysplastic syndrome or acute myelogenous leukemia who underwent a HSCT at Memorial Sloan Kettering Cancer Center and survived at least 1 year post HSCT. Patients underwent either a TBI- (N=18) or busulfan- (N=4) based cytoreduction followed by T-cell-depleted transplants from alternative donors. Twenty patients were alive at time of the study with a 5- and 10-year overall survival of 100 and 84% and no evidence of chronic GvHD. Among the 18 patients receiving a TBI-based regimen, 11 (61%) had persistent hemochromatosis, 4 (22%) developed hypothyroidism, 7 (39%) had insulin resistance and 5 (27%) developed hypertriglyceridemia after transplant. Eleven of 16 evaluable patients (68%), receiving TBI, developed gonadal dysfunction. Two patients who received a TBI-based regimen died of squamous cell carcinoma. One patient developed hemochromatosis, hypothyroidism and gonadal dysfunction after busulfan-based cytoreduction. TBI appears to be a risk factor for malignant and endocrine late effects in the FA host. Multidisciplinary follow-up of patients with FA (including cancer screening) is essential for early detection and management of late complications, and improving long-term outcomes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Wagner JE, Eapen M, MacMillan ML, Harris RE, Pasquini R, Boulad F et al. Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia. Blood 2007; 109: 2256–2262.
Chaudhury S, Auerbach AD, Kernan NA, Small TN, Prockop SE, Scaradavou A et al. Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia. Br J Haematol 2008; 140: 644–655.
Bhatia S . Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up. Expert Rev Hematol 2011; 4: 437–452.
Sanders JE, Woolfrey AE, Carpenter PA, Storer BE, Hoffmeister PA, Deeg HJ et al. Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemia. Blood 2011; 118: 1421–1428.
Jakubowski AA, Small TN, Young JW, Kernan NA, Castro-Malaspina H, Hsu KC et al. T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin. Blood 2007; 110: 4552–4559.
Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancer, 2013.
American Diabetes A. Standards of medical care in diabetes—2013. Diabetes Care 2013; 36 (Suppl 1): S11–S66.
Chemaitilly W, Boulad F, Oeffinger KC, Sklar CA . Disorders of glucose homeostasis in young adults treated with total body irradiation during childhood: a pilot study. Bone Marrow Transplant 2009; 44: 339–343.
Svahn J, Dufour C . Fanconi anemia—learning from children. Pediatr Rep 2011; 3 (Suppl 2): e8.
Giri N, Batista DL, Alter BP, Stratakis CA . Endocrine abnormalities in patients with Fanconi anemia. J Clin Endocrinol Metab 2007; 92: 2624–2631.
Rosenberg PS, Greene MH, Alter BP . Cancer incidence in persons with Fanconi anemia. Blood 2003; 101: 822–826.
Guardiola P, Socie G, Li X, Ribaud P, Devergie A, Esperou H et al. Acute graft-versus-host disease in patients with Fanconi anemia or acquired aplastic anemia undergoing bone marrow transplantation from HLA-identical sibling donors: risk factors and influence on outcome. Blood 2004; 103: 73–77.
Deeg HJ, Leisenring W, Storb R, Nims J, Flowers ME, Witherspoon RP et al. Long-term outcome after marrow transplantation for severe aplastic anemia. Blood 1998; 91: 3637–3645.
Curtis RE, Metayer C, Rizzo JD, Socie G, Sobocinski KA, Flowers ME et al. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood 2005; 105: 3802–3811.
Boulad F, Gillio A, Small TN, George D, Prasad V, Torok-Castanza J et al. Stem cell transplantation for the treatment of Fanconi anaemia using a fludarabine-based cytoreductive regimen and T-cell-depleted related HLA-mismatched peripheral blood stem cell grafts. Br J Haematol 2000; 111: 1153–1157.
Kutler DI, Singh B, Satagopan J, Batish SD, Berwick M, Giampietro PF et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 2003; 101: 1249–1256.
Rosenberg PS, Alter BP, Socie G, Gluckman E . Secular trends in outcomes for Fanconi anemia patients who receive transplants: implications for future studies. Biol Blood Marrow Transplant 2005; 11: 672–679.
Kutler DI, Auerbach AD, Satagopan J, Giampietro PF, Batish SD, Huvos AG et al. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch Otolaryngol Head Neck Surg 2003; 129: 106–112.
Lustig JP, Lugassy G, Neder A, Sigler E . Head and neck carcinoma in Fanconi's anaemia—report of a case and review of the literature. Eur J Cancer B Oral Oncol 1995; 31B: 68–72.
Themeli M, Petrikkos L, Waterhouse M, Bertz H, Lagadinou E, Zoumbos N et al. Alloreactive microenvironment after human hematopoietic cell transplantation induces genomic alterations in epithelium through an ROS-mediated mechanism: in vivo and in vitro study and implications to secondary neoplasia. Leukemia 2010; 24: 536–543.
Khan FM, Sy S, Louie P, Ugarte-Torres A, Berka N, Sinclair GD et al. Genomic instability after allogeneic hematopoietic cell transplantation is frequent in oral mucosa, particularly in patients with a history of chronic graft-versus-host disease, and rare in nasal mucosa. Blood 2010; 116: 1803–1806.
Peffault de Latour R, Porcher R, Dalle JH, Aljurf M, Korthof ET, Svahn J et al. Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience. Blood 2013; 122: 4279–4286.
Deeg HJ, Socie G, Schoch G, Henry-Amar M, Witherspoon RP, Devergie A et al. Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood 1996; 87: 386–392.
Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109: 4586–4588.
Trottier BJ, Burns LJ, DeFor TE, Cooley S, Majhail NS . Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2-MRI-measured liver iron content. Blood 2013; 122: 1678–1684.
St Pierre TG, El-Beshlawy A, Elalfy M, Al Jefri A, Al Zir K, Daar S et al. Multicenter validation of spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration. Magn Reson Med 2014; 71: 2215–2223.
Rose SR, Myers KC, Rutter MM, Mueller R, Khoury JC, Mehta PA et al. Endocrine phenotype of children and adults with Fanconi anemia. Pediatr Blood Cancer 2012; 59: 690–696.
Eyal O, Blum S, Mueller R, Smith FO, Rose SR . Improved growth velocity during thyroid hormone therapy in children with Fanconi anemia and borderline thyroid function. Pediatr Blood Cancer 2008; 51: 652–656.
Bizzarri C, Pinto RM, Ciccone S, Brescia LP, Locatelli F, Cappa M . Early and progressive insulin resistance in young, non-obese cancer survivors treated with hematopoietic stem cell transplantation. Pediatr Blood Cancer 2015; 62: 1650–1655.
Chow EJ, Simmons JH, Roth CL, Baker KS, Hoffmeister PA, Sanders JE et al. Increased cardiometabolic traits in pediatric survivors of acute lymphoblastic leukemia treated with total body irradiation. Biol Blood Marrow Transplant 2010; 16: 1674–1681.
Taskinen M, Saarinen-Pihkala UM, Hovi L, Lipsanen-Nyman M . Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood. Lancet 2000; 356: 993–997.
Oudin C, Simeoni MC, Sirvent N, Contet A, Begu-Le Coroller A, Bordigoni P et al. Prevalence and risk factors of the metabolic syndrome in adult survivors of childhood leukemia. Blood 2011; 117: 4442–4448.
Rovo A, Tichelli A, Passweg JR, Heim D, Meyer-Monard S, Holzgreve W et al. Spermatogenesis in long-term survivors after allogeneic hematopoietic stem cell transplantation is associated with age, time interval since transplantation, and apparently absence of chronic GvHD. Blood 2006; 108: 1100–1105.
Savani BN, Rezvani K, Mielke S, Montero A, Kurlander R, Carter CS et al. Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2006; 107: 1688–1695.
Chemaitilly W, Sklar CA . Endocrine complications of hematopoietic stem cell transplantation. Endocrinol Metab Clin North Am 2007; 36: 983–998 ix.
Nabhan SK, Bitencourt MA, Duval M, Abecasis M, Dufour C, Boudjedir K et al. Fertility recovery and pregnancy after allogeneic hematopoietic stem cell transplantation in Fanconi anemia patients. Haematologica 2010; 95: 1783–1787.
Mosher CE, Redd WH, Rini CM, Burkhalter JE, DuHamel KN . Physical, psychological, and social sequelae following hematopoietic stem cell transplantation: a review of the literature. Psychooncology 2009; 18: 113–127.
Rusiewicz A, DuHamel KN, Burkhalter J, Ostroff J, Winkel G, Scigliano E et al. Psychological distress in long-term survivors of hematopoietic stem cell transplantation. Psychooncology 2008; 17: 329–337.
Kearney JA, Hay JL, Halpern L, Boulad F . Peritransplant psychiatric evaluation of patients with fanconi anemia. J Pediatr Hematol Oncol 2012; 34: 163–168.
Acknowledgements
We thank the fellows, residents, nurses and nurse practitioners of the Department of Pediatrics at MSK and Rachel Lehrman and Joseph Olechnowicz for data management and editorial assistance. AP is the recipient of a St Baldrick’s Fellowship. We thank the Fanconi Anemia Research Fund for their support. This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Anur, P., Friedman, D., Sklar, C. et al. Late effects in patients with Fanconi anemia following allogeneic hematopoietic stem cell transplantation from alternative donors. Bone Marrow Transplant 51, 938–944 (2016). https://doi.org/10.1038/bmt.2016.32
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2016.32
This article is cited by
-
Long-term skin findings in patients with Fanconi anemia after allogeneic hematopoietic stem cell transplantation
Bone Marrow Transplantation (2021)
-
Long-term outcome in patients with Fanconi anemia who received hematopoietic stem cell transplantation: a retrospective nationwide analysis
International Journal of Hematology (2021)
-
Effective CRISPR/Cas9-mediated correction of a Fanconi anemia defect by error-prone end joining or templated repair
Scientific Reports (2019)
-
Bone Marrow Mesenchymal Stem Cells Carrying FANCD2 Mutation Differ from the Other Fanconi Anemia Complementation Groups in Terms of TGF-β1 Production
Stem Cell Reviews and Reports (2018)
-
Patterns and frequency of renal abnormalities in Fanconi anaemia: implications for long-term management
Pediatric Nephrology (2018)